Dr. Miltie N9+ About
Now you can do all of that from home!
With a user-friendly device that syncs with your smartphone
The Dr. Miltie and N9+ Story
Virtual care is no longer a convenience. It is becoming an essential part of modern healthcare. As patients seek easier access to medical support from home and providers look for better ways to deliver timely, accurate care, remote patient examination technology is helping close the gap between telehealth visits and in-person clinical evaluation.
That is where N9+ and Dr. Miltie come together.
The N9+ was created to support a more complete virtual care experience by helping patients collect clinically relevant health data from the comfort of home. Through the Dr. Miltie N9+ platform, this data can be securely shared with a physician, giving providers the information they need to make more informed decisions during remote consultations.
The Dr. Miltie N9+ offers a cost-effective, smartphone-compatible virtual exam solution designed to improve remote patient care. The platform helps physicians evaluate patients more accurately, create timely diagnosis and treatment plans, and reduce unnecessary in-office visits when appropriate.
With a user-friendly design, clinically meaningful data collection, and flexible system architecture, the Dr. Miltie N9+ integrates into existing healthcare workflows and proprietary systems. This makes it easier for providers, health systems, and care organizations to expand telehealth services without sacrificing the quality of patient information.
For patients, the Dr. Miltie N9+ brings care closer to home. For physicians, it delivers better insight at the point of virtual care. For healthcare organizations, it supports a more connected, efficient, and scalable telehealth model.
With the Dr. Miltie N9+, care is always at hand.
N9+, formerly known as MyHomeDoc, is an innovative medical technology company founded in 2016. The company graduated from Sanara Ventures, a joint investment platform of Teva Pharmaceuticals and Philips Healthcare, and has offices in Israel and the United States.
